Accelerating Drug Discovery With an Automated Single-Cell Workflow
White Paper Apr 08, 2021
Single-cell sequencing is quickly becoming a standard tool in biological research due to the scale and depth of insight it provides across diverse cell populations. The pharmaceutical industry is exploiting single-cell approaches to identify novel therapeutic targets and accelerate promising assets through development.
Consistency and reproducibility are critical throughout the entire drug development process. In the absence of robust workflows, variability in gene expression libraries can be introduced, particularly for long-term studies, research distributed across physical sites and multi-phase global projects.
Download this whitepaper to discover a single-cell workflow that can:
• Produce consistent and reproducible results
• Accelerate drug discovery and development
• Increase productivity and reduce error
Related White Papers
The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.READ MORE
Over the past two decades, monoclonal antibodies (mAbs) have been one of the most dominant segments of the biotherapeutics market. Ensuring mAbs’ safety and efficacy is vital but is made complicated by the fact that antibodies can have a tendency to aggregate during production, decreasing efficacy and increasing the risk of immunogenicity.READ MORE